尽管出现亏损，但 AbCellera 仍超出盈利预期，但由于分析师观点不一，其股价下跌。 AbCellera beat earnings estimates despite a loss, but its stock dropped on mixed analyst views.

AbCellera Biologics公司报告,每季度每股损失1.2美元,粗略估计损失5美元,收入1 708万美元,远远超过预期的755万美元。 AbCellera Biologics reported a quarterly loss of $0.12 per share, beating estimates by $0.05, with revenue of $17.08 million, far exceeding the $7.55 million expected. 尽管全年预计净差为493.42 % , 每股损失0.59美元,但该公司的股票在周五在混合分析师评分中跌至3.91美元。 Despite a negative net margin of 493.42% and a loss of $0.59 per share projected for the full year, the company’s stock fell to $3.91 on Friday amid mixed analyst ratings. 协商一致的评分仍然“坚持”,目标价格为7.75美元。 The consensus rating remains “Hold” with a $7.75 target price. 该公司继续开发代谢/内分泌紊乱和外皮皮炎抗体疗法,机构所有权占61.42%。 The firm continues developing antibody therapies for metabolic/endocrine disorders and atopic dermatitis, with institutional ownership at 61.42%.